Candace Makeda Makeda Moore

Dr. Candace Makeda Makeda Moore

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2022 in Intelligence-Based Medicine
Verified
Journal Article
Open access
CMCandace Makeda Makeda Moore
Candace Makeda Makeda Moore

29 December 2021 in American Journal of Infection Control
Verified
Journal Article
Closed access
RARonen Arbel
Ronen Arbel
CMCandace Makeda Makeda Moore
Candace Makeda Makeda Moore
Ruslan SergienkoRuslan Sergienko
Ruslan Sergienko
JPJoseph Pliskin
Joseph Pliskin

20 February 2022 in The American Journal of Cardiology
Verified
Journal Article
Closed access
AHAriel Hammerman
Ariel Hammerman
CMCandace Makeda Makeda Moore
Candace Makeda Makeda Moore
EAEnis Aboalhasan
Enis Aboalhasan
JAJoseph Azuri
Joseph Azuri
RARonen Arbel
Ronen Arbel

21 June 2022 in Postgraduate Medicine
Verified
Journal Article
Closed access
AHAriel Hammerman
Ariel Hammerman
CMCandace Makeda Makeda Moore
Candace Makeda Makeda Moore
EAEnis Aboalhasan
Enis Aboalhasan
JAJoseph Azuri
Joseph Azuri
RARonen Arbel
Ronen Arbel
Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP1a), reduces the risk of major adverse cardiovascular events (MACE) in patients with Type 2 diabetes mellitus (T2DM). An oral version of ...

23 October 2023 in Journal of Open Source Software
Verified
Journal Article
Open access
PDF file
CMCandace Makeda Makeda Moore
Candace Makeda Makeda Moore
WBWalter Baccinelli
Walter Baccinelli
OSOleg Sivokon
Oleg Sivokon
RWRob Warnaar
Rob Warnaar
EOEline Oppersma
Eline Oppersma

18 August 2021 in medRxiv
Verified
Preprint
Open access
PDF file
CMCandace Makeda Makeda Moore
Candace Makeda Makeda Moore
Ruslan SergienkoRuslan Sergienko
Ruslan Sergienko
RARonen Arbel
Ronen Arbel
Background In 2021 a new variant of SARS-CoV-2, which came to be called the alpha variant, spread around the world. There were conflicting reports on this COVID-19 variant strain’s potentially increased lethality. In Israel, this strain became predominant in a very short time period. Methods COVID-19 mortality and case fatality rates were examined in Israel in terms of weekly and cumulative numbers. Results COVID-19 case fatality rates in Israel rose quickly at the beginning of the pandemic and peaked in May 2020. The highest crude mortality came later in the second and third waves, but case the case fatality rates did not rise in 2021 with the increasing dominance of the alpha variant. Conclusions Based on the results of examining case-fatality and mortality rates, we concluded that while the alpha variant of the virus raised mortality, in line with the fact that it is more infectious than wild-type, once this strain was caught by patients in Israel, it was not more likely to kill them than the original strain